{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:01:45Z","timestamp":1771063305332,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.bbmt.2019.11.014","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T02:59:19Z","timestamp":1574045959000},"page":"486-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-5533","authenticated-orcid":false,"given":"Ashish","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-5466","authenticated-orcid":false,"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathryn","family":"Jennissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weston P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.11.014_bib0001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0002","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0003","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0004","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2008-03-140830","article-title":"Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes","volume":"112","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.bbmt.2018.03.011","article-title":"A comparison of the myeloablative conditioning regimen fludarabine\/busulfan with cyclophosphamide\/total body irradiation, for allogeneic stem cell transplantation in the modern era: a cohort analysis","volume":"24","author":"Gooptu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0007","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as preparative regimen before allogeneic hematopoietic cell transplantation: systemic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2013-05-502385","article-title":"Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome","volume":"123","author":"Lindemans","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0010","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0011","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0012","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0013","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0014","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0015","series-title":"The Statistical Analysis of Failure Time Data","first-page":"168","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0016","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0017","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https:\/\/www.R-project.org. Accessed 18 March 2019."},{"key":"10.1016\/j.bbmt.2019.11.014_bib0018","unstructured":"Therneau T. A package for survival analysis in S. version 2.38. Available at:https:\/\/CRAN.R-project.org\/package=survival. Accessed 18 March 2019."},{"key":"10.1016\/j.bbmt.2019.11.014_bib0019","unstructured":"Gray R.J.cmprsk: Subdistribution analysis of competing risks. Available at:https:\/\/CRAN.R-project.org\/package=cmprsk. Accessed 20 March 2019."},{"key":"10.1016\/j.bbmt.2019.11.014_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clml.2014.04.006","article-title":"Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen","volume":"14","author":"Fedele","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0021","first-page":"12064","article-title":"Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis","volume":"8","author":"Lei","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0022","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1705164","article-title":"Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)","volume":"36","author":"Myers","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0023","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0024","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2016.10.019","article-title":"Allele-level HLA matching impacts key outcomes following umbilical cord blood transplantation for inherited metabolic disorders","volume":"23","author":"Mallhi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0026","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bbmt.2008.07.013","article-title":"Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0027","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.11.014_bib0028","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/mt.2009.87","article-title":"Systemic correction of storage disease in MPS I NOD\/SCID mice using the sleeping beauty transposon system","volume":"17","author":"Aronovich","year":"2009","journal-title":"Mol Ther"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119307815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119307815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:26Z","timestamp":1761059366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119307815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1083879119307815"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}